- 1 SB236
- 2 200482-2
- 3 By Senator Melson
- 4 RFD: Judiciary
- 5 First Read: 04-APR-19

SB236 1 2 3 ENGROSSED 4 5 6 7 A BILL TO BE ENTITLED 8 9 AN ACT 10 Relating to the medical use of marijuana; to amend 11 Sections 13A-12-213, 13A-12-214, 13A-12-214.2, 13A-12-214.3, 12 13 and 20-2-214, Code of Alabama 1975, and to add a new Chapter 2A to Title 20, Code of Alabama 1975; to create the CARE Act; 14 15 to exempt from the crime of unlawful possession or use of marijuana a resident diagnosed with a qualifying condition who 16 has a valid medical cannabis card for the medical use of 17 18 cannabis; to establish the Alabama Medical Cannabis Commission and provide for its membership and duties; to provide for a 19 20 patient registry system of qualified patients and designated 21 caregivers and provide for issuance of medical cannabis cards 22 to registrants; to license the cultivation, processing, transportation, manufacturing, packaging, dispensing, and sale 23 24 of cannabis; to authorize the Department of Agriculture and 25 Industries to inspect licensed facilities; to impose taxes; to 26 create a Medical Cannabis Fund and provide for its proceeds and expenditures; to provide definitions; to extend Carly's 27

Law; to make conforming changes to Leni's Law; to repeal 1 Leni's Law at a later date; to require reporting to the 2 Legislature; and in connection therewith would have as its 3 purpose or effect the requirement of a new or increased 4 5 expenditure of local funds within the meaning of Amendment 621 of the Constitution of Alabama of 1901, now appearing as 6 7 Section 111.05 of the Official Recompilation of the Constitution of Alabama of 1901, as amended. 8 BE IT ENACTED BY THE LEGISLATURE OF ALABAMA: 9 10 Section 1. Sections 13A-12-213, 13A-12-214, 13A-12-214.2, 13A-12-214.3, and 20-2-214, Code of Alabama 11 1975, are amended to read as follows: 12 13 "\$13A-12-213. 14 "(a) A person commits the crime of unlawful 15 possession of marihuana marijuana in the first degree if, 16 except as otherwise authorized: 17 "(1) He or she possesses marihuana marijuana for 18 other than personal use; or "(2) He or she possesses marihuana marijuana for his 19 20 or her personal use only after having been previously 21 convicted of unlawful possession of marihuana marijuana in the 22 second degree or unlawful possession of marihuana marijuana 23 for his or her personal use only. 24 "(b) Commencing on the effective date of the act 25 adding this subsection, a person has not committed the crime 26 of unlawful possession of marijuana if the person is in possession of a valid medical cannabis card issued pursuant to 27

1	Chapter 2A of Title 20, unless there is reasonable cause to
2	believe that the information contained on the medical cannabis
3	card is false or falsified, the medical cannabis card has been
4	obtained by means of fraud, or the person is otherwise in
5	violation of Chapter 32 of Title 2 or a rule adopted pursuant
6	to that chapter.
7	" (b) <u>(c)</u> Unlawful possession of marihuana <u>marijuana</u>
8	in the first degree pursuant to subdivision (1) of subsection
9	(a) is a Class C felony.
10	" (c) <u>(d)</u> Unlawful possession of marihuana <u>marijuana</u>
11	in the first degree pursuant to subdivision (2) of subsection
12	(a) is a Class D felony.
13	"\$13A-12-214.
14	"(a) A person commits the crime of unlawful
15	possession of marihuana <u>marijuana</u> in the second degree if,
16	except as otherwise authorized, he possesses marihuana
17	<u>marijuana</u> for his personal use only.
18	"(b) Commencing on the effective date of the act
19	adding this subsection, a person has not committed the crime
20	of unlawful possession of marijuana if the person is in
21	possession of a valid medical cannabis card issued pursuant to
22	Chapter 2A of Title 20, unless there is reasonable cause to
23	believe that the information contained on the medical cannabis
24	card is false or falsified, the medical cannabis card has been
25	obtained by means of fraud, or the person is otherwise in
26	violation of Chapter 2A of Title 20 or a rule adopted pursuant
27	to that chapter.

1	" (b)<u>(</u>c) Unlawful possession of marihuana <u>marijuana</u>
2	in the second degree is a Class A misdemeanor.
3	"§13A-12-214.2.
4	"(a) This section shall be known and may be cited as
5	"Carly's Law."
6	"(b) As used in this section, the following words
7	shall have the following meanings:
8	"(1) AUTHORIZED BY THE UAB DEPARTMENT. Authorized by
9	the UAB Department means that Cannabidiol (CBD) has been
10	prescribed by a health care practitioner employed by or on
11	behalf of the UAB Department.
12	"(2) CANNABIDIOL (CBD). [13956-29-1]. A
13	(nonpsychoactive) cannabinoid found in the plant Cannabis
14	sativa L. or any other preparation thereof that is essentially
15	free from plant material, and has a THC level of no more than
16	3 percent. Also known as (synonyms):
17	2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-p
18	entyl-1,3-benzenediol;
19	trans-(-)-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol;
20	(-)-Cannabidiol; (-)-trans-Cannabidiol; Cannabidiol (7CI);
21	D1(2)-trans-Cannabidiol.
22	"(3) DEBILITATING EPILEPTIC CONDITION. Epilepsy or
23	other neurological disorder, or the treatment of epilepsy or
24	other neurological disorder that, as diagnosed by a
25	board-certified neurologist under the employment or authority
26	of the UAB Department, produces serious, debilitating, or
27	life-threatening seizures.

"(4) UAB DEPARTMENT. The Department of Neurology at
 the University of Alabama at Birmingham, its successors, or
 any subdivisions.

"(c) In a prosecution for the unlawful possession of
marijuana under the laws of this state, it is an affirmative
and complete defense to the prosecution that the defendant has
a debilitating epileptic condition and used or possessed
cannabidiol (CBD) pursuant to a prescription authorized by the
UAB Department.

10 "(d) In a prosecution for the unlawful possession of marijuana under the laws of this state, it is an affirmative 11 12 and complete defense to the prosecution that the defendant 13 possessed cannabidiol (CBD) because he or she is the parent or caretaker of an individual who has a debilitating epileptic 14 15 condition and who has a prescription for the possession and use of cannabidiol (CBD) as authorized by the UAB Department, 16 17 and where the parent or caretaker's possession of the CBD is 18 on behalf of and otherwise for the prescribed person's use 19 only.

"(e) An agency of this state or a political subdivision thereof, including any law enforcement agency, may not initiate proceedings to remove a child from the home of a parent based solely upon the parent's or child's possession or use of cannabidiol (CBD) as authorized by this section.

"(f) A prescription for the possession or use of cannabidiol (CBD) as authorized by this section shall be provided exclusively by the UAB Department for a debilitating

Page 5

epileptic condition. Health care practitioners of the UAB 1 2 Department shall be the sole authorized source of any prescription for the use of cannabidiol (CBD), and shall be 3 the sole authorized source to use cannabidiol (CBD) in or as a 4 5 part of the treatment of a person diagnosed with a debilitating epileptic condition. A health care practitioner 6 7 of the UAB Department shall have the sole authority to determine the use or amount of cannabidiol (CBD), if any, in 8 9 the treatment of an individual diagnosed with a debilitating 10 epileptic condition.

"(q) The UAB Department and any UAB School of 11 Medicine affiliated pediatric training entity, including any 12 13 authorized physician, nurse, attendant, or agent thereof, shall not be subject to prosecution for the unlawful 14 15 possession, use, distribution, or prescription of marijuana under the laws of this state for its activities arising 16 17 directly out of or directly related to the prescription or use 18 of cannabidiol (CBD) in the treatment of individuals diagnosed with a debilitating epileptic condition. 19

20 "(h) The UAB Department will establish a research 21 and development study purposed to determine medical uses and 22 benefits of cannabidiol (CBD) for individuals with 23 debilitating epileptic conditions.

"(i) The UAB Department and any UAB School of
Medicine affiliated pediatric training entity, including any
authorized physician, nurse, attendant or agent thereof, shall
not be subject to prosecution for the unlawful possession,

Page 6

use, or distribution of marijuana under the laws of this state for its activities arising directly out of or directly related to the department's research and development activities in pursuit of medical benefits and uses of cannabidiol (CBD), as long as the prescription, treatment or use of cannabidiol (CBD) is provided only to individuals diagnosed with a debilitating epileptic condition.

8 "(j) Pursuant to the filing requirements of Rule 9 15.3 of the Alabama Rules of Criminal Procedure, the defendant 10 shall produce a valid prescription, certification of a 11 debilitating epileptic condition, and the name of the 12 prescribing health care professional authorized by the UAB 13 Department.

14 "(k) This section is repealed July 1, 2019 January
15 1, 2021.

16 "(1) The Alabama Medical Cannabis Commission created 17 pursuant to Section 2-2A-7, added by Section 2 of the act 18 adding this amendatory language, may recommend to the 19 Legislature other potential studies that universities in the 20 state may wish to conduct regarding the medical use of 21 cannabidiol (CBD).

22 "(1) (m) Nothing in this section shall be construed 23 to allow or accommodate the prescription, testing, medical 24 use, or possession of any other form of Cannabis other than 25 that defined by this section.

26 "§13A-12-214.3.

"(a)(1) This section shall be known and may be cited
 as Leni's Law.

3 "(2) For the purposes of this section, the following
4 terms shall have the following meanings:

5 "a. CANNABIDIOL (CBD). [13956-29-1]. A
6 (nonpsychoactive) cannabinoid found in the plant Cannabis
7 sativa L. or any other preparation thereof that is free from
8 plant material, and has a THC level

9 (delta-9-tetrahydrocannibinol) of no more than three percent 10 relative to CBD according to the rules adopted by the Alabama 11 Department of Forensic Sciences. Also known as (synonyms): 12 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-p 13 entyl-1,3-benzenediol;

14 trans-(-)-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol; 15 (-)-Cannabidiol; (-)-trans-Cannabidiol; Cannabidiol (7CI); 16 D1(2)-tran-Cannabidiol and that is tested by a independent 17 third-party laboratory.

18 "b. DEBILITATING MEDICAL CONDITION. A chronic or 19 debilitating disease or medical condition including one that 20 produces seizures for which a person is under treatment.

"(3) In addition to the affirmative defense provided in Section 13A-12-214.2, in a prosecution for the unlawful possession of marijuana in the second degree under Section 13A-12-214, it is an affirmative and complete defense that the defendant used or possessed CBD if the defendant satisfies either of the following:

27

"a. He or she has a debilitating medical condition.

"b. He or she is the parent or legal guardian of a
 minor who has a debilitating medical condition, and the CBD is
 being used by the minor.

4 "(4) An agency of this state or a political
5 subdivision thereof, including any law enforcement agency, may
6 not initiate proceedings to remove a child from the home of a
7 parent or guardian, nor initiate any child protection action
8 or proceedings, based solely upon the parent's or child's
9 possession or use of CBD as allowed by this section.

10 "(5) Nothing in this section shall be construed to 11 require the various individual or group insurance 12 organizations providing protection, indemnity, or insurance 13 against hospital, medical, or surgical expenses, or health 14 maintenance organizations to provide payment or reimbursement 15 for prescriptions of CBD.

16 "(6) Nothing in this section shall be construed to 17 allow or accommodate the prescription, testing, medical use, 18 or possession of any other form of Cannabis other than that 19 defined in this section.

20 "(b) The Legislature finds and declares the21 following:

"(1) This section is intended to authorize only the limited use of nonpsychoactive CBD as defined in this section only for specified debilitating medical conditions that produce seizures, and is not intended as a generalized authorization of medical marijuana. 1 "(2) It is the intent of the Legislature to maintain 2 existing criminal prohibitions of marijuana, except as 3 expressly provided in existing law or as expressly provided in 4 this section.

5

"§20-2-214.

6 "(a) The following persons or entities shall be 7 permitted access to the information in the controlled 8 substances database, subject to the limitations indicated 9 below:

10 "(1) Authorized representatives of the certifying boards; provided, however, that access shall be limited to 11 information concerning the licensees of the certifying board, 12 13 however, authorized representatives from the Board of Medical 14 Examiners may access the database to inquire about certified 15 registered nurse practitioners (CRNPs), or certified nurse 16 midwives (CNMs) that hold a Qualified Alabama Controlled 17 Substances Registration Certificate (QACSC).

18 "(2) A licensed practitioner approved by the department who has authority to prescribe, dispense, or 19 20 administer controlled substances. The licensed practitioner's 21 access shall be limited to information concerning himself or 22 herself, registrants who possess a Qualified Alabama 23 Controlled Substances Registration Certificate over whom the 24 practitioner exercises physician supervision or with whom they 25 have a joint practice agreement, a certified registered nurse practitioner and a certified nurse midwife with a Qualified 26 27 Alabama Controlled Substances Registration Certificate over

whom the practitioner exercises professional oversight and 1 2 direction pursuant to an approved collaborative practice agreement, a current patient of the practitioner, and 3 individuals seeking treatment from the practitioner. 4 5 Practitioners shall have no requirement or obligation under this article to access or check the information in the 6 7 controlled substances database prior to prescribing, 8 dispensing, or administering medications or as part of their 9 professional practice. However, the applicable licensing 10 boards, in their discretion, may impose such a requirement or obligation by regulations. 11

12 "(3) A qualified physician concerning a qualified 13 patient, as those terms are defined in Section 2-2A-1, and 14 where access is made pursuant to Section 2-2A-21.

15 "(3)(4) A licensed physician approved by the 16 department who has authority to prescribe, dispense, or 17 administer controlled substances may designate up to two 18 employees who may access the database on the physician's 19 behalf.

20 "(4)(5) A licensed certified registered nurse 21 practitioner or a licensed certified nurse midwife approved by 22 the department who is authorized to prescribe, administer, or dispense pursuant to a Qualified Alabama Controlled Substances 23 24 Registration Certificate; provided, however, that access shall 25 be limited to information concerning a current or prospective 26 patient of the certified registered nurse practitioner or certified nurse midwife. 27

1 "(5)(6) A licensed assistant to physician approved 2 by the department who is authorized to prescribe, administer, 3 or dispense pursuant to a Qualified Alabama Controlled 4 Substances Registration Certificate; provided, however, that 5 access shall be limited to information concerning a current 6 patient of the assistant to the physician or an individual 7 seeking treatment from the assistant to physician.

8 "(6) (7) A licensed pharmacist approved by the department, provided, however, that access is limited to 9 10 information related to the patient or prescribing practitioner designated on a controlled substance prescription that a 11 pharmacist has been asked to fill. Pharmacists shall have no 12 13 requirement or obligation to access or check the information in the controlled substances database prior to dispensing or 14 15 administering medications or as part of their professional 16 practices.

17 "(7)(8) State and local law enforcement authorities 18 as authorized under Section 20-2-91, and federal law 19 enforcement authorities authorized to access prescription 20 information upon application to the department accompanied by 21 a declaration that probable cause exists for the use of the 22 requested information.

23 "(8)(9) Employees of the department and consultants 24 engaged by the department to operate the controlled substances 25 database; provided, however, that access shall be limited to 26 operating and administering the database, conducting 27 departmental research when approved by the Information Release Review Committee, and implementing a research request
 authorized under subsection (b).

"(9)(10) The prescription drug monitoring program of 3 any of the other states or territories of the United States, 4 5 if recognized by the Alliance for Prescription Drug Monitoring Programs under procedures developed, certified, or approved by 6 7 the United States Department of Justice or the Integrated Justice Information Systems Institute or successor entity 8 subject to or consistent with limitations for access 9 10 prescribed by this chapter for the Alabama Prescription Drug Monitoring Program. 11

12 "(10)(11) Authorized representatives of the Alabama 13 Medicaid Agency; provided, however, that access shall be 14 limited to inquiries concerning possible misuse or abuse of 15 controlled substances by Medicaid recipients.

16 "(b) Subject to the approval of the Information 17 Release Review Committee, the department may release or 18 publish de-identified aggregate statewide and regional 19 information for statistical, research, or educational 20 purposes.

"(1) Prior to being released or published, all information that identifies, or could reasonably be used to identify, a patient, a prescriber, a dispenser, or any other person who is the subject of the information, shall be removed, and at a minimum, such de-identification of the information shall comply with 45 C.F.R. §164.514(b)(2), as amended.

"(2) Release of information shall be made pursuant 1 2 to a written data use agreement between the requesting individual or entity and the department." 3 Section 2. Chapter 2A commencing with Section 4 20-2A-1, is added to Title 20, Code of Alabama 1975, to read 5 as follows: 6 7 Article 1. General Provisions. §20-2A-1. 8 9 This chapter shall be known and may be cited as the 10 Compassionate Access, Research Expansion Act or CARE Act. §20-2A-2. 11 As used in this chapter, the following terms have 12 13 the following meanings: (1) CANNABIS. All parts of any plant of the genus 14 15 cannabis, whether growing or not, including the seeds, extractions of any kind from any part of the plant, and every 16 compound, derivative, mixture, product, or preparation of the 17 18 plant. (2) CAREGIVER. A resident of this state who meets 19 20 the requirements of subsection (c) of Section 20-2A-5 and has 21 agreed to assist with the medical use of cannabis of another 22 individual with, or by applying for, a medical cannabis card. (3) COMMISSION. The Alabama Medical Cannabis 23 24 Commission created pursuant to Section 20-2A-7. 25 (4) DISPENSARY. A licensed, enclosed, secure 26 building that may include attached storage units, where 27 cannabis and related supplies are maintained, stored, and sold to patients and caregivers, which is not physically connected to a cannabis cultivation, processing, or manufacturing facility.

4 (5) MEDICAL CANNABIS CARD. A valid card issued
5 pursuant to this chapter or a valid card from another state
6 that has legalized the use of medical cannabis.

(6) MEDICAL USE. The acquisition, possession, use,
delivery, transfer, or administration of cannabis authorized
by this chapter. The term does not include possession, use, or
administration of cannabis that was not purchased or acquired
from a licensed dispensary.

(7) PATIENT REGISTRY. A documented, electronic, and
 integrated system for receiving physician certifications and
 patient registrations and issuing medical cannabis cards.

(8) PHYSICIAN CERTIFICATION. A qualified physician's
authorization for a qualified patient to use cannabis for
medical use.

(9) QUALIFIED PATIENT. A resident of this state who
 has been diagnosed by a qualified physician with a qualifying
 condition, who receives a physician certification, and who
 otherwise meets the requirements to obtain a medical cannabis
 card.

(10) QUALIFIED PHYSICIAN. A physician who holds an
active license to practice medicine under Chapter 24 of Title
34 who meets the qualifications under Section 20-2A-20.

(11) QUALIFYING CONDITION. Any of the following
 conditions diagnosed by a qualified physician who may

recommend the use of cannabis to treat the symptoms associated 1 2 with the condition: a. Autism Spectrum Disorder (ASD). 3 b. Epilepsy. 4 5 c. Cancer. d. Degenerative or pervasive neurological disorders. 6 7 e. Glaucoma. f. HIV/AIDS. 8 9 g. Multiple sclerosis. 10 h. Muscle disorders, including those associated with 11 muscle spasms. i. Opioid addiction. 12 13 j. Pain syndromes or pain associated with other 14 medical conditions. 15 k. Post Traumatic Stress Disorder (PTSD). 1. Any additional conditions approved by the 16 17 commission by rule. 18 §20-2A-3. (a) The Alabama Medical Cannabis Commission shall 19 20 implement this chapter by making medical grade cannabis grown 21 in Alabama available to qualified patients. 22 (b) The commission shall administer and enforce this chapter and all rules adopted pursuant to this chapter. 23 24 (c) This chapter supersedes state criminal and civil 25 laws pertaining to the acquisition, possession, use, cultivation, manufacturing, processing, research and 26 development, and sale of medical cannabis. The acquisition, 27

possession, use, cultivation, manufacturing, processing, research and development, or sale of medical cannabis in compliance with this chapter, and as approved by the commission, does not constitute a violation of Article 5 of Chapter 12 of Title 13A, or any other law to the contrary. \$20-2A-4.

7 All data related to the implementation of this chapter, including, but not limited to, application forms, 8 licensing information, physician certifications, registration 9 10 of medical cannabis card holders and caregivers, compliance, and the status of cannabis research programs must be 11 maintained in a secure system developed or procured by the 12 13 commission. Data may not be sold, and patient information shall remain confidential and not be transferred or sold. 14

15

§20-2A-5.

(a) An individual may not acquire, possess, or use a
medical cannabis product without a valid medical cannabis card
issued pursuant to this chapter, except as provided in
subsection (d). A medical cannabis card may only be issued to
a qualified patient or designated caregiver.

(b) A qualified patient must be 19 years of age or
older; a resident of this state; and be diagnosed with a
qualifying condition by a qualified physician. If a qualified
patient is under 19 years of age, only a caregiver may
purchase or administer cannabis to the qualified patient.

(c) A designated caregiver must be 19 years of age
or older, a resident of this state, have no ownership interest

in or contract or employment relationship with a licensed 1 2 dispensary, and either be designated by a qualified patient as the caregiver or be the parent or legal guardian of a minor 3 diagnosed with a qualifying condition. A designated caregiver 4 5 may lawfully acquire and possess cannabis, but not use 6 cannabis under this chapter without the careqiver actually 7 being diagnosed with a qualifying condition and issued a medical cannabis card as a gualified patient. 8

9 (d) This state shall recognize and give reciprocity 10 to medical cannabis cards issued in other states. A cardholder 11 from another state is allowed temporary access to dispensaries 12 in this state under the conditions authorized by the 13 commission in accordance with rules adopted pursuant to the 14 Alabama Administrative Procedure Act.

15 \$20-2

16

§20-2A-6.

This chapter does not do any of the following:

17 (1) Require an insurer, organization for managed
18 care, health benefit plan, or any person who provides coverage
19 for a medical or health care service to pay for or reimburse a
20 person for costs associated with the medical use of cannabis.

(2) Require any employer to permit or accommodate an employee's use or possession of medical cannabis, to allow the medical use of cannabis in the workplace, or to modify the job or working conditions of an individual who engages in the medical use of cannabis that are based upon the reasonable business purposes of the employer. (3) Prohibit an employer from refusing to hire,
 discharging, disciplining, or otherwise taking an adverse
 employment action against an individual with respect to hire,
 tenure, terms, conditions, or privileges of employment because
 of that individual's use or possession of medical cannabis.

6 (4) Prohibit an employer from establishing and 7 enforcing a drug testing policy or from implementing a 8 drug-free workforce program established in accordance with 9 Article 13, commencing with Section 25-5-330, of Chapter 5 of 10 Title 25.

(5) Interfere with any federal restrictions on
employment, including, but not limited to regulations adopted
by the United States Department of Transportation in Title 49,
Code of Federal Regulations.

(6) Permit an individual to commence a cause of
action against an employer for refusing to hire, discharging,
disciplining, or otherwise taking an adverse employment action
against an individual with respect to hire, tenure, terms,
conditions, or privileges of employment related to medical
cannabis.

21

\$20-2A-7.

(a) There is created the Alabama Medical Cannabis
Commission. Members of the commission shall be as follows,
with initial members appointed not later than August 30, 2019:

(1) Three members appointed by the Governor, one of
whom is a physician licensed to practice medicine in this
state, certified in the specialty of neurology; one of whom is

Page 19

1 a physician licensed to practice medicine in this state with a 2 practice that involves pain management; and one of whom is a 3 licensed pharmacist. The initial terms shall be four, three, 4 and two years, respectively.

5 (2) Three members appointed by the President Pro Tempore of the Senate, one of whom is a physician licensed to 6 7 practice medicine in this state, certified in the specialty of oncology; one of whom is a general physician licensed to 8 9 practice medicine in this state and practices in a rural, 10 underserved community; and one of whom has experience in multiple crop development and agricultural practices. The 11 initial terms shall be one, four, and three years, 12 13 respectively.

(3) Three members appointed by the Speaker of the
House of Representatives, one of whom is a physician licensed
to practice medicine in this state, certified in the specialty
of psychiatry; one of whom has a background and experience in
mental health or substance abuse; and one of whom has
professional experience in agricultural systems management.
Initial terms shall be two, one, and four years, respectively.

(4) Two members appointed by the Attorney General,
one of whom has experience advocating for patients in a health
care setting. Initial terms shall be three and two years,
respectively.

(b) A member may not have any interest, financial or
otherwise, direct or indirect, in any dispensary, cultivator,
or manufacturer licensed as such in this state. Any current

public official, candidate for public office, current public
 employee, or registered lobbyist may not serve as a member.

3 (c) Members must be at least 30 years of age,
4 citizens of the United States, and residents of this state for
5 at least five continuous years immediately preceding their
6 appointment. The appointing officers shall coordinate their
7 appointments so that diversity of gender, race, and
8 geographical areas is reflective of the makeup of this state.

9 (d) After initial appointments, each member shall 10 serve a term of four years, but may be reappointed for one 11 additional term. If at any time there is a vacancy, a 12 successor member shall be appointed by the respective 13 appointing officer to serve for the remainder of the term. 14 Members may be removed for cause by the Governor.

(e) The commission shall elect from the membership
one member to serve as chair and one member to serve as
vice-chair.

(f) While serving on business of the commission, members shall be entitled to a per diem of five hundred dollars (\$500) per day, as well as actual travel expenses incurred in the performance of duties as a member, as other state employees are paid, when approved by the chair.

(g) Except as provided in subsection (h), the
commission shall meet each month and hold other meetings for
any period of time as may be necessary for the commission to
transact and perform its official duties and functions. A
majority of members of the commission constitutes a quorum for

the transaction of any business, or in the performance of any 1 2 duty, power, or function of the commission, and the concurrence of a majority of those present and voting in any 3 matter within its duties is required for a determination of 4 5 matters within its jurisdiction. The commission may hold a special meeting at any time it deems necessary and advisable 6 7 in the performance of its official duties. A special meeting 8 may be called by the chair, or upon the written request of two 9 or more members. All members shall be duly notified by the 10 commission director of the time and place of any regular or special meeting at least five days in advance of any meeting. 11 The chair is responsible for setting and keeping a meeting 12 13 schedule that ensures the commission meets the requirements of 14 this chapter. Members may not miss more than three meetings in 15 one calendar year.

(h) (1) The commission shall hold a minimum of two
regularly scheduled meetings each month in the first 12 months
commencing no later than November 1, 2019, in order to do all
of the following:

a. Expeditiously create and publish an applicationform for medical cannabis cards.

b. Establish a website for public access andinformation.

c. Review, approve, or deny fast track licenseapplications.

26 d. Adopt rules pursuant to the Alabama27 Administrative Procedure Act to implement this chapter.

1 (2) After adopting initial rules, issuing the fast 2 track licenses, establishing a patient registry, and 3 publishing the patient medical cannabis card application forms 4 and procedures, the commission may reduce meetings to one per 5 month or vote on a schedule appropriate for meeting all 6 obligations under this chapter regarding patient medical 7 cannabis cards.

(i) (1) The commission may appoint a director to 8 9 serve at the pleasure of the commission. The director's salary 10 shall be fixed by the commission. The director shall be at least 30 years of age and have been a citizen and resident of 11 this state for at least five years prior to appointment. The 12 13 director shall be licensed to practice law in this state. The director is the chief administrative officer of the 14 15 commission, and all personnel employed by the commission shall be under the director's direct supervision. The director is 16 solely responsible to the commission for the administration 17 18 and enforcement of this chapter and is responsible for the performance of all duties and functions delegated by the 19 20 commission.

(2) The director shall maintain all records of the
commission and also serve as secretary of the commission. The
director shall prepare and keep the minutes of all meetings
held by the commission, including a record of all business
transacted and decisions rendered by the commission. A copy of
the record of the minutes and business transacted and

decisions rendered shall be kept on file at the commission's
 main office and shall be available for public inspection.

3 (3) The director shall act and serve as hearing
4 officer when designated by the commission and shall perform
5 such duties as the regular hearing officer.

6 (j) The commission may appoint an assistant director 7 who shall perform all duties and functions which may be assigned by the director or the commission. The assistant 8 9 director, if licensed to practice law in this state, may also 10 be designated by the commission to sit, act, and serve as a hearing officer, and when designated as a hearing officer, the 11 12 assistant director may perform the same duties and functions 13 as the regular hearing officer.

(k) In any action or suit brought against the members of the commission in their official capacity in a court of competent jurisdiction, to review any decision or order issued by the commission, service of process issued against the commission may be lawfully served or accepted by the director on behalf of the commission as though the members of the commission were personally served with process.

(1) The commission, in consultation with the
Department of Agriculture and Industries, shall appoint a
chief inspection and enforcement officer who meets all of the
following qualifications and requirements:

(1) Be under the immediate supervision of thedirector.

```
27
```

(2) Be at least 30 years of age.

1

2

(3) Has been a citizen and resident of this state for at least five years prior to appointment.

3 (4) Has experience and training in agricultural4 inspections.

5 (m) The chief inspection and enforcement officer 6 shall be reimbursed for travel expenses in a manner similar to 7 state employees.

8 (n) The director, assistant director, and chief 9 inspection and enforcement officer shall be reimbursed for 10 actual travel expenses as other state employees are paid, when 11 approved by the chair. The director, chief inspection and 12 enforcement officer, and all other inspection and enforcement 13 personnel shall be employed on a full-time basis only.

(o) The commission shall retain legal counsel
familiar with the requirements of this chapter and medical
cannabis licensing and best practices in other states in order
to assist the commission and staff with establishing a
functional program and achieving compliance with applicable
laws.

20

§20-2A-8.

(a) A member of the commission and any individual
employed by the commission may not have any interest,
financial or otherwise, either direct or indirect, in any
dispensary, cultivator, or manufacturer licensed under this
chapter. In addition, a member or employee of the commission
may not have any family member who is employed by any
dispensary, cultivator, or manufacturer or who holds any

cannabis license in this state. A member or employee of the 1 2 commission or his or her family member may not have an interest of any kind in any building, fixture, or premises 3 occupied by any person licensed under this chapter; and may 4 5 not own any stock or have any interest of any kind, direct or indirect, pecuniary or otherwise, by a loan, mortgage, gift, 6 7 or guarantee of payment of a loan, in any dispensary, 8 cultivator, or manufacturer licensed under this chapter.

9 (b) A member or employee of the commission may not 10 accept any gift, favor, merchandise, donation, contribution, 11 or any article or thing of value, from any person licensed 12 under this chapter.

13 (c) Any individual violating this section shall be 14 terminated from employment or position, and as a consequence, 15 the individual shall forfeit any pay or compensation which 16 might be due.

17 (d) For purposes of this section, family member
18 includes a spouse, child, parent, or sibling, by blood or
19 marriage.

20 (e) A violation of this section is a Class C
21 misdemeanor.

Article 2. Medical Cannabis Patient Registry and
 Medical Cannabis Cards.

\$20-2A-20.

24

Before being approved as a qualified physician, and before each license renewal, a physician must successfully complete 10 hours of continuing medical education that

addresses cannabis treatment for medical conditions and 1 2 encompasses the requirements of this chapter and any rules 3 adopted pursuant to this chapter. Any course and examination, if applicable, shall be administered at least annually and may 4 5 be offered in a distance learning format, including an 6 electronic, online format that is available upon request. The 7 commission may contract with a third party or the Board of Medical Examiners to administer this section, provided the 8 9 commission approves any course material and examination. The 10 price of the training may not exceed five hundred dollars (\$500). 11

12

§20-2A-21.

(a) A qualified physician may issue a physician
 certification only if the qualified physician does all of the
 following:

(1) Conducts a physical examination while physically
 present in the same room as the patient and a full assessment
 of the medical history of the patient.

19 (2) Diagnoses the patient with at least one20 qualifying condition.

(3) Determines that the medical use of cannabis would likely outweigh the potential health risks for the patient and documents that determination in the patient's medical record.

(4) Reviews the patient's controlled drug
 prescription history in the controlled substance prescription

1 database established under Article 10 of Chapter 2 of this 2 title.

3 (5) Reviews the patient registry and confirms that
4 the patient does not have an active physician certification
5 from another qualified physician.

(6) Obtains the voluntary and informed written 6 7 consent of the patient to use cannabis for medical use each 8 time the qualified physician issues a physician certification 9 for the patient, which shall be maintained in the patient's 10 medical record. The patient, or the patient's parent or legal guardian if the patient is a minor, must sign the informed 11 12 consent acknowledging that the qualified physician has 13 sufficiently explained its content. The qualified physician shall use a standardized informed consent form adopted by rule 14 15 by the commission, that must include, at a minimum, information relating to all of the following: 16

a. The federal and state classification of cannabisas a Schedule I controlled substance.

b. The approval and oversight status of cannabis bythe Food and Drug Administration.

c. The current state of research on the efficacy of
 cannabis to treat the qualifying condition or conditions.

23

d. The potential for addiction.

e. The potential effect that cannabis may have on a patient's coordination, motor skills, and cognition, including a warning against operating heavy machinery, operating a motor vehicle, or engaging in activities that require a person to be
 alert or respond quickly.

3

f. The potential side effects of cannabis use.

g. The risks, benefits, and drug interactions ofcannabis.

h. That the patient's de-identified health
information contained in the patient's medical record,
physician certification, and patient registry may be used for
research purposes or used to monitor compliance with this
chapter, as further provided in subsection (h).

(b) If medically appropriate, the qualified physician issuing a physician certification shall refer the qualified patient to a physician certified in a speciality relevant to the diagnosis of a qualifying condition.

(c) As the issuer of a physician certification, the
qualified physician shall register electronically the named
qualified patient in the patient registry in a manner
determined by the commission.

(d) When registering a qualified patient under
subsection (c), a qualified physician may limit the cannabis
that a qualified patient may obtain from a dispensary based on
quantity, type, or dosage.

(e) Before a qualified physician may reissue a
physician certification, he or she shall do all of the
following:

(1) Determine if the patient still meets the
 criteria for issuing a physician certification under
 subsection (a).

4 (2) Determine that, over a period of not less than
5 six months, the qualified patient's health or the symptoms of
6 the qualifying condition have significantly improved.

7 (3) Identify and document in the qualified patient's
8 medical records whether the qualified patient experienced
9 either of the following related to the medical use of
10 cannabis:

a. An adverse drug interaction with any prescriptionor nonprescription medication.

b. A reduction in the use of, or dependence on,other types of controlled substances.

(f) A qualified physician shall update the patient
registry within seven days after any change is made to the
original physician certification to reflect the change.

(g) A qualified physician shall deactivate the
registration of a qualified patient and the patient's
caregiver in the following circumstances:

(1) When the qualified physician no longerrecommends cannabis for medical use for the patient.

(2) If there is clear evidence, in accordance with
 rules adopted by the commission, that a patient may be
 diverting or misusing cannabis.

26 (3) When the physician-patient relationship is27 terminated.

1 (h) The commission may monitor physician 2 certification and patient registration in the patient registry for practices that could facilitate unlawful diversion or 3 misuse of cannabis and shall recommend disciplinary action to 4 5 the Board of Medical Examiners as appropriate. Monitoring may 6 include reviewing the medical records of patients, in 7 accordance with state and federal law, on whose behalf a qualified physician issued physician certifications, in order 8 to ascertain whether the patients were diagnosed with the 9 10 qualifying condition specified by the qualified physician on the physician certification. 11

(i) The commission shall adopt rules to implement
this section which shall include criteria for reissuing
physician certifications and may include guidelines on dosage,
quantities, and types of cannabis products that may be
recommended by qualified physicians for a particular
qualifying condition.

18

§20-2A-22.

(a) In order to commence, use, and maintain a
reliable patient registry system, by no later than July 31,
2020, the commission shall do all of the following:

(1) Establish and administer an integrated,
electronic patient registry system that does all of the
following:

a. Receives physician certifications from qualified
 physicians in the registry database.

Page 31

b. Includes in the registry database for each 1 2 qualified patient registrant the names of the qualified patient and the patient's designated caregiver, if applicable, 3 and information relating to the physician certification, 4 5 including the name of the qualified physician, the diagnosed qualifying condition or conditions, and the type and quantity 6 7 of cannabis product recommended by the qualified physician. c. Provides a procedure for keeping the information 8 9 on a qualified patient up-to-date. 10 d. Tracks the medical cannabis card application process through issuance or denial. 11 e. Tracks medical cannabis cards that are denied, 12 13 issued, revoked, suspended, or reinstated. f. Provides access as further provided in subsection 14 15 (b). (2) Adopt rules to implement this section that 16 17 include criteria by which medical cannabis cards may be 18 revoked, suspended, and renewed. The rules may not prohibit the issuance or use of a medical cannabis card based on an 19 20 arrest for any felony or misdemeanor, unless the arrest is for 21 a violation of this chapter. (3) Begin issuing medical cannabis card requests 22 23 that meet the requirements of this chapter. 24 (b) The patient registry system shall be accessible 25 to the following: 26 (1) Law enforcement agencies in order to verify that an individual in possession of a medical cannabis card is 27

lawfully in possession of the card and to avoid counterfeiting
 of cards.

3 (2) Health care practitioners licensed to prescribe
4 prescription drugs in order to ensure proper care for patients
5 before medications are prescribed that may interact with
6 medical cannabis.

7 (3) Licensed dispensaries in order to verify that an
8 individual in possession of a medical cannabis card is
9 lawfully in possession of the card and to determine whether
10 there are any specific recommendations or limits on quantity,
11 type, or dosage of cannabis products that the cardholder may
12 receive.

(c) No later than July 31, 2020, the commission shall ensure that a process is available, as part of the patient registry system, for qualified physicians to register a physician certification, report any change in the status of a qualifying condition, or deactivate a physician certification.

(d) A medical cannabis cardholder must be locatablein the registry system with adequate identifying information.

21

§20-2A-23.

(a) The commission shall develop an application form
to be completed by qualified patients and designated
caregivers in order to be placed on the patient registry and
issued a medical cannabis card. The application form shall
include all of the following:

Page 33

1 (1) Proof that the applicant is 19 years of age or 2 older and a resident of this state by means of state-issued 3 photo identification.

4 (2) For an applicant who is a designated caregiver,5 both of the following:

a. Proof that the caregiver meets the qualifications
in subsection (c) of Section 20-2A-5.

b. The names of each qualified patient for whom the
caregiver provides care, including a confirmation of the
caregiver relationship in writing from each qualified patient,
unless the caregiver is the legal guardian of a minor.

12

13

(3) A full-face, passport-type, color photographtaken within 90 days immediately preceding registration.

14 (4) An application fee of sixty-five dollars (\$65),
15 or other amount as determined by the commission.

16 (5) Any other information deemed relevant by the 17 commission.

(b) The commission shall issue a medical cannabis
card to an individual once the commission has received a
completed application and fee from the applicant and a
physician certification has been registered by a qualified
physician through the patient registry system.

(c) Medical cannabis cards shall be resistant to
 counterfeiting and tampering and, at a minimum, shall include
 all of the following:

(1) The name, address, and date of birth of the
qualified patient or caregiver, as applicable.

- (2) A photograph of the qualified patient or
 caregiver, as applicable.
- 3 (3) Identification of the cardholder as a qualified4 patient or a caregiver.

(4) The expiration date of the card.

6 (d) A medical cannabis card expires two years from 7 the date of issuance.

- 8 (e) Medical cannabis cards may be renewed in 9 accordance with rules adopted by the commission and upon 10 payment of a renewal fee of sixty-five dollars (\$65), or other 11 amount as determined by the commission.
- (f) The commission, through a procedure adopted by rule, shall notify the qualified physician who issued a physician certification and registered a qualified patient in the patient registry, that the qualified patient has been issued a medical cannabis card.

17 (g) The commission may suspend or revoke a medical18 cannabis card if the cardholder does any of the following:

- 19 (1) Provides misleading, incorrect, false, or20 fraudulent information to the commission.
- 21 (2) Falsifies, alters, or otherwise modifies a
 22 medical cannabis card.
- 23 (3) Violates the requirements of this chapter or any24 rule adopted under this chapter.
- 25 §20-2A-24.

5

(a) When a qualified patient has a designated
 caregiver, only the designated caregiver is authorized to

purchase cannabis; a patient with a designated caregiver may not purchase cannabis.

3 (b) A caregiver may receive compensation from the
4 qualified patient or other entity for any services provided to
5 the qualified patient.

6 (c) A caregiver may not provide care to more than 10 7 qualified patients at any given time.

8 Article 3. Cultivation, Processing, and Dispensing
9 of Medical Cannabis.

10

§20-2A-40.

(a) All of the cultivation, processing,
transportation, packaging, and dispensing and selling of any
form or derivative of medical cannabis is subject to licensing
and regulation under this article.

(b) The commission shall consult with the Department of Agriculture and Industries when adopting rules relating to the cultivation and processing of cannabis, and the department shall provide assistance and advice to the commission as needed. The commission shall bear the administrative costs incurred by the department pursuant to this subsection.

21

§20-2A-41.

This state hereby preemptively regulates medical cannabis from seed to sale to use and shall reasonably regulate and control all aspects of the medical cannabis industry to meet the stated intent of this chapter. Any county or municipality seeking to ban the cultivation, processing, manufacture, or sale of medical cannabis within its jurisdiction is authorized to do so by a two-thirds vote of the local governing body; provided, that the vote occurs no later than July 31, 2020.

4

§20-2A-42.

5 (a) In order to facilitate an initial level of medical grade cannabis product availability and avoid a 6 7 program delay dependent on rulemaking, the commission may 8 review and issue approved provisional fast track licenses for 9 the cultivation, processing, transportation, manufacturing, 10 packaging, and dispensing and selling of medical cannabis, in an expedited manner, before the commission has adopted a final 11 regulatory program as provided in Section 20-2A-43. Any fast 12 13 track licenses issued by the commission shall be done in a manner that provides access to medical cannabis throughout 14 15 rural and urban populations, taking into account the racial and economic makeup of the state. A provisional fast track 16 17 license shall not be finally approved or denied until an 18 on-site inspection of all facilities operated by the fast track licensee has been conducted. 19

(b) The commission shall issue a final approval or
denial of a fast track license not later than January 1, 2021.
\$20-2A-43.

(a) Not later than July 1, 2021, the commission
shall adopt rules that provide for all of the following:

(1) Determining the various types of licenses and
the activities and functions that may be conducted by a
licensee and the area of operation of a licensee.

(2) Qualifications and requirements for licensees,
 as further provided in subsection (b).

(3) The number of licenses the commission will issue 3 and locations of facilities, based on market demand for 4 5 stand-alone dispensaries, stand-alone cultivation, and stand-alone processing or manufacturing facilities, and for 6 7 similar vertically integrated operations, and taking into 8 account the racial and economic makeup of the state, the 9 unemployment rate, the need for agricultural and other 10 business opportunities in communities, access to health care, infrastructure, and other factors the commission deems 11 12 relevant in providing the greatest benefits to the residents 13 of this state.

14 (4) The on-site inspection process to be conducted 15 at each facility of an applicant prior to being issued a 16 license, as well as ongoing on-site inspections of the 17 facilities of a licensee.

18 (5) Standards and procedures for the revocation,19 suspension, and nonrenewal of licenses.

(6) Standards and procedures for the renewal of
licenses, which shall include, but not be limited to, payment
of a renewal fee and an additional criminal background check.

(7) Standards and procedures for the transfer of
licenses. Any transfer of a license or change of ownership
shall comply with the requirements of a new licensee,
including approval by the commission and payment of the
license fee.

1 (8) Measures or standards to ensure any cannabis 2 product remains secure at all times, including, but not limited to, requirements that licensed facilities remain 3 securely enclosed and locked as appropriate. 4 5 (9) Any other measures necessary to protect health, safety, and welfare. 6 7 (b) When applying for a license under this article, an applicant shall submit the following information to the 8 9 commission: 10 (1) Proof of residence. The applicant's majority ownership must be attributable to an individual with proof of 11 residency in this state for a continuous period of no less 12 13 than five years preceding the application date. 14 (2) A detailed business and operations plan that 15 includes, at a minimum, all of the following: a. Identification of each individual with a 16 17 financial interest in the applicant. 18 b. Identification of each business entity with a financial interest in the applicant. 19 c. A proposed location with street address, which 20 21 may not be within a 1,000 foot radius of any pre-kindergarten, 22 elementary, or secondary school. d. A full list of activities such as cultivation, 23 24 processing, packaging, transporting, or dispensing and 25 selling, to be undertaken by the applicant. 26 e. A summary of projected tenant improvements, production schedule, products, production capacity, standard 27

1 operating procedures, target customer base, and projected open
2 date.

f. Identification of all corporate officers and
summaries of the business experience for each individual
expected to be responsible for facility operations.

6 (3) Payment of a license fee. The commission may 7 alter the fee, by rule, based on guidelines that consider the 8 geographical area or other factors the commission deems 9 relevant in making sure that licensees are representative of 10 the racial and economic makeup of this state; provided, 11 however, a license fee for a stand-alone facility shall be no 12 less than ten thousand dollars (\$10,000).

(4) Payment of a non-refundable application fee to
cover the administrative costs of processing a license
application.

(5) A criminal background check. All owners,
officers, board members, and managers of the applicant, shall
pass a Federal Bureau of Investigation Level 2 background
screening process, which shall be documented on the
application materials prior to final review and approval.

(6) An attestation statement and signature from a responsible corporate officer of an applicant affirming that the contents of any application are true and correct under penalty of perjury to the best of the officer's personal knowledge.

26 (7) Any other information the commission deems27 appropriate.

1 (c) When determining whether to issue or deny a 2 license under this section, the commission shall consider the 3 applicant's business plan as it relates to all of the 4 following:

5 (1) The applicant's ability to capitalize and 6 conduct operations as proposed in its business plan, including 7 business experience in related fields such as agriculture, 8 real estate, development, manufacturing, or retail sales.

9 (2) The applicant's history of business activities 10 as it applies to the entity and the individuals who are the 11 entity's owners, officers, and managers.

12 (3) The proposed location of all operations as being 13 suitable for all activities, not inconsistent with applicable 14 zoning, and the applicant's ability to serve an identifiable 15 geographic area.

16 §20-2A-44.

(a) A licensed dispensary shall be required by the
commission to inspect a medical cannabis card before
dispensing any cannabis product.

(b) The commission, by rule, shall establish
guidelines and standards to ensure that cannabis is only
dispensed to individuals holding a valid medical cannabis card
and dispensed in accordance with the physician certification
with regard to quantity, type, or dosage of cannabis products,
if applicable.

```
26 §20-2A-45.
```

In order to ensure that all cannabis products sold 1 2 in the state maintain product quality to protect the health 3 and welfare of state residents, the commission shall procure and use a secure, online system for seed-to-sale tracking of 4 all medical cannabis in the state in order to ensure that 5 medical cannabis may not be produced from, obtained from, sold 6 7 to, or transferred to, any location outside of this state. \$20-2A-46. 8 The commission, by rule, may provide guidelines for 9 10 establishing a fair market value or base price on the retail sale of cannabis products. 11 \$20-2A-47. 12 13 The commission shall provide annual written reports, with the first due no later than July 31, 2020, tracking 14 15 implementation of this chapter. The report shall be made publicly available and posted on the commission's website. The 16 17 report shall include all of the following: 18 (1) The number of patients applying for and receiving medical cannabis cards. 19 20 (2) The qualifying conditions identified to obtain 21 the medical cannabis cards. (3) Comments from physicians and other health care 22 23 providers and from pharmacists. 24 (4) Revenues and expenses of card issuance and 25 business licensing. 26 (5) Relevant developments in other states' cannabis 27 laws.

(6) Relevant scientific research. 1 2 (7) Applicable tax revenue. 3 (8) The commission's operating budget. (9) Any other information available to the 4 5 commission that would inform public officials of how this 6 chapter affects the public. 7 \$20-2A-48. The commission, by rule, shall establish protocols 8 9 for product testing, which shall be conducted during 10 cultivation, processing, and dispensing to ensure that all dispensed medical cannabis is consistently medical grade. The 11 protocols for testing shall include the following, as well as 12 13 a determination of corresponding tolerance limits: 14 (1) Cannabinoid potency. 15 (2) Terpene profiles. 16 (3) Heavy metals. (4) Chemical contamination, such as residual 17 18 solvents remaining after extraction and concentration. (5) Microbials, including pathogenic microbials. 19 20 (6) Mycotoxins. 21 (7) Residual insecticides, fungicides, herbicides, 22 and growth regulators used during cultivation. (8) Residual solvents. 23 24 \$20-2A-49. 25 (a) There is created a special account in the State Treasury to be known as the Medical Cannabis Fund. 26 Expenditures from the Medical Cannabis Fund may be made only 27

by the commission to implement and administer this chapter.
 Specifically, the Medical Cannabis Fund includes all of the
 following:

4

(1) Fees collected by the commission.

5 (2) Tax proceeds collected pursuant to subsections
6 (b) and (c) of Section 3 of the act adding this language.

7 (3) Any moneys appropriated by the Legislature for8 the initial operation of the commission.

9 (b) Upon a determination by the Legislature that the 10 commission has established sufficient revenues for the 11 administration of this chapter, the Legislature shall direct 12 the state Comptroller to transfer any excess balance that is 13 in the Medical Cannabis Fund to the General Fund.

Section 3. (a) A county or municipality may tax the sale of medical cannabis in accordance with Article 1, commencing with Section 40-23-1, of Chapter 23 of Title 40, Code of Alabama 1975; provided, that the tax may not exceed 2.1 percent of the gross proceeds of the sales.

(b) Commencing January 1, 2020, there is levied, in addition to all other taxes of every kind now imposed by law, and shall be collected and remitted in accordance with Article 1, commencing with Section 40-23-1, of Chapter 23 of Title 40, Code of Alabama 1975, a tax on the gross proceeds of the sales of medical cannabis when sold at retail in this state at the rate of nine percent of the gross proceeds of the sales.

26 (c)(1) Commencing January 1, 2021, there is levied
 27 an annual privilege tax on every person doing business under

Chapter 2A of Title 20, Code of Alabama 1975, in Alabama. The 1 2 tax shall accrue as of January 1 of every taxable year, or in the case of a taxpayer licensed under Chapter 2A of Title 20, 3 Code of Alabama 1975, during the year, or doing business in 4 5 this state for the first time, as of the date the taxpayer is licensed to do business under Chapter 2A of Title 20, Code of 6 7 Alabama 1975. The rate of tax shall be 10 percent of the net worth in Alabama for the taxable year. For purposes of this 8 9 subdivision, a taxpayer's net worth in Alabama shall be 10 determined by apportioning the taxpayer's net worth computed under Section 40-14A-23, Code of Alabama 1975, in the same 11 12 manner as prescribed for apportioning income during the 13 determination period for purposes of the income tax levied by Chapter 18 of Title 40, Code of Alabama 1975, or the manner in 14 15 which the income would be apportioned if the taxpayer were 16 subject to the income tax.

(2) The annual return required by this subsection is due no later than the corresponding federal income tax return, as required to be filed under federal law. In the case of a taxpayer's initial return, the annual return shall be due no later than two and one-half months after the taxpayer is licensed to do business, or commences business, in Alabama.

(3) The Department of Revenue may grant a reasonable
extension of time for filing returns under rules adopted by
the department. No extension shall be for more than six
months.

(4) The annual medical cannabis privilege tax shall 1 2 be reported on forms and in the manner as prescribed by rule by the department. The failure to receive a form from the 3 department shall not relieve a taxpayer from liability for any 4 5 tax, penalty, or interest otherwise due. The tax due, as 6 reported, shall constitute an admitted liability for that 7 amount. The department may compute and assess additional tax, 8 penalty, and interest against a taxpayer as provided in Chapter 2A of Title 40, Code of Alabama 1975. 9

10 (d) The Department of Revenue shall adopt rules to11 implement this section.

12 Section 4. Although this bill would have as its 13 purpose or effect the requirement of a new or increased 14 expenditure of local funds, the bill is excluded from further 15 requirements and application under Amendment 621, now 16 appearing as Section 111.05 of the Official Recompilation of 17 the Constitution of Alabama of 1901, as amended, because the 18 bill defines a new crime or amends the definition of an existing crime. 19

20 Section 5. This act shall become effective 21 immediately following its passage and approval by the 22 Governor, or its otherwise becoming law.

1		
2		
3	Senate	
4 5 6	Read for the first time and referred to the Senate committee on Judiciary	04-APR-19
7 8 9	Read for the second time and placed on the calen- dar with 1 substitute and	25-APR-19
10	Read for the third time and passed as amended \ldots	0.9-MAY-19
11 12 13 14	Patrick Harris, Secretary.	